Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. March 08, 2019. Ifeanyi Onyeacholem.

Executive Summary

The market for breast cancer imaging, biopsy and tissue-sparing treatment products is expected to reach $5.8bn in 2022, a CAGR of 5.9% from 2017. Many radiologists believe that digital breast tomosynthesis will become the gold standard. See what Kaiser Permanente's radiologist Ifeanyi Onyeacholem said about it here.

"It clears up a lot of questions a 2D mammogram cannot necessarily clear up. The technology uses X-rays, but instead of a mammogram that's in 2D, it is putting a 3D object into a 3D image and creates slices through the breast that is similar to a CT scan – so on each level it helps us decide if it's regular tissue or more than that." –Ifeanyi Onyeacholem, radiologist, Kaiser Permanente, San Diego

Click here for a free trial of Medtech Insight


Related Content

Market Intel: Breast Imaging Market Driven By AI, Technological Innovation





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts